期刊文献+

肿瘤专业发展趋势及我区肿瘤专业发展设想 被引量:1

Present Status and Prospect of Medical Oncology
下载PDF
导出
摘要 目的综述肿瘤内科专业的最新进展及发展趋势,为我区肿瘤学发展寻求突破方向和理论依据。方法通过Pubmed及CNKI检索近5年来肿瘤内科相关专业英文及中文文献,结合文献对国内外肿瘤内科的现状和发展趋势进行分析、归纳及总结。结果近年来肿瘤学发展迅速,肿瘤发病谱有新的变化,肿瘤的筛查监测新方法不断出现,尤其突出的是分子靶向治疗时代开始,逐渐成为肿瘤治疗最重要的方法,而分子靶向治疗同时衍生的个体化治疗更是将肿瘤药物治疗推向一个新的时代,综合治疗方法有了更新的突破,肿瘤的治愈率更高,生存期更长。结论我区的肿瘤内科治疗处于临床发展阶段,需进一步完善基础设施的建设,而治疗方法仍然是跟进国外,依靠完善基础设施,突出特色医疗,加强科研合作,才能在未来肿瘤治疗方法中有新的突破。 Objective To review the latest progress and development trend of medical ontology so as to seek breakthrough orientation and theoretical basis for the development of oneology department in our district. Methods The current situation and development of medical oncology were analyzed and summarized by reviewing related literature of medical oncology published on Pubmed and CNKI in recent five years. Results In recent years, the ontology develops so fast that oncology disease spectrum is changing. New tumor markers and new assays were found. The most important one is the beginning of molecularly targeted therapy, which gradually becomes the most important treatment method of cancer. Individual treatment, derived from molecularly targeted therapy, brings great progress for tumor drug treatment. Means and methods of comprehensive treatment have new breakthroughs. We have a higher tumor cure rate and patients have longer survival time. Conclusion The medical treatment of tumors in our district is still in clinical development stage. Better infrastructure should he constructed and followed up abroad. We can make progress in tumor treatment in future by highlighting characteristic, strengthening the scientific research and the cooperation.
作者 吴铁鹰
出处 《解放军医药杂志》 CAS 2013年第2期1-5,共5页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 国家自然科技基金(C03031901)
关键词 肿瘤 分子生物学 肿瘤治疗方案 Neoplasm Molecular biology Antineoplastic protocol
  • 相关文献

参考文献22

  • 1Goss P E,Ingle J N, Ales-Martinez J E, et al. Exemes- tane for breast-cancer prevention in postmenopausal women[J]. N EnglJMed,2011,364(25):2381-2391.
  • 2Aberle D R,Adams A M,Berg C D,et al. Reduced lung- cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011 , 365:395-409.
  • 3Wen Shi. Solid tumor agents dominate the future of bio- marker[ C/OL]. Oncology Business Review. oncbiz, com, 2012, March :6-11.
  • 4Saurabh Aggarwal. Targeted cancer therapies[ J]. Nature reviews ,2010,9 ( 6 ) :427-428.
  • 5Kris M G, Johnson B E, Kwiatkowski D J,et al. Identifi- cation of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma:The NCI's Lung Canc- er Mutation Consortium(LCMC)[ J]. J Clin Oncol,2012, 29 (suppl) :477s, abstr CRA7506.
  • 6Paik P K, Adnan Hasanovic, Lu Wang, et al. Multiplex testing for driver mutations in squamous cell carcinomas of the lung[J]. J Clin Oncol, 2012(suppl) :abstr 7505.
  • 7Ramaswamy Govindan, Hammerman P S, Hayes D N, et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung [ J ]. J Clin Oncol, 2012 ( sup- pl) : abstr 7006.
  • 8James Chih-Hsin Yang, Martin H Schuler, Nobuyuki Yamamoto,et al. LUX-Lung 3 : A randomized, open-la- bel,phase III study of afatinib versus pemetrexed and cis- platin as first-line treatment for patients with advanced ad- enocarcinoma of the lung harboring EGFR-activating mu- tations [ J ]. J Clin Oncol,2012 (suppl) : abstr LB A7500.
  • 9Schuler M H,Planehard D,Yang J C,et al. Interim anal- ysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/ge- fitinib (E/G) in a trial of afatinib plus paelitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy[ J]. J Clin Oncol,2012,30( Sup- pl) : abstr7557.
  • 10Shaw A T, et al. Impact of crizotinib on survival in pa- tients with advanced, ALK-positive NSCLC compared with historical controls. Presented at the 47th Annual Meeting of the American Society of Clinical Oncology [ C]. American: Chicago, 2011.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部